Figure 2
Effect of single-nucleotide polymorphism (SNP) variants (a) rs11052877 (CD69), (b) rs4910008 (GALNTL4) on change in Disease Activity Score (cDAS28) in response to tocilizumab in All. Biomarker-positive/negative patients are defined as those carrying the major or minor allele and genetic model as indicated in each forest plot. The 95% confidence intervals are indicated for the point estimate of the difference in mean cDAS28 between biomarker-positive and -negative patients. Values are presented for all subjects and separated by treatment line, dose and drug. Interpretation of effect size estimations for patients previously exposed to anti-tumor necrosis factor (anti-TNF) inadequate responder (IR) (RADIATE7) or methotrexate naïve (AMBITION10) are confounded by the low number of patients in this cohort leading to broad confidence intervals, but are presented for completeness. BM+, biomarker positive, BM−, biomarker negative.
